Currently, two PARP inhibitors, olaparib and talazoparib, are approved in the United States and Europe as monotherapies for human epidermal growth factor 2 (HER2)-negative, gBRCAm, advanced breast cancer. Here, PARP1 is linked to breast carcinoma.